Skip to content
DataLookout
Menu

NCT07246564

Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis

StatusActive, Not Recruiting
PhasePhase 4
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 13 versions: 13 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 14 words
    • Enrollment closed, study ongoing
    • Secondary endpoints: details revised at 4 of 7 entries
    • Site details revised at 12 of 12 sites
  2. Minor Site details revised at 1 of 12 sitesv12
  3. Minor Study sites: 11 to 12v11
  4. Minor Study sites: 9 to 11v10
  5. Minor Study sites: 8 to 9v9
Show 7 earlier versionsHide 7 earlier versions
  1. Minor Study sites: 7 to 8v8
  2. Minor Study sites: 6 to 7v7
  3. Minor Study sites: 5 to 6v6
  4. Minor Study sites: 4 to 5v5
  5. Minor Study sites: 3 to 4v4
  6. Minor Study sites: 2 to 3v3
  7. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    • Start date changed from estimate of Dec 2025 to Dec 1, 2025
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change from Baseline to Day 43 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) score in the first Treatment Cycle
Timeframe: Baseline to Day 43 (in first treatment cycle)

Secondary (7)

MG-ADL responder (≥2.0-point improvement from Baseline) at Day 43 in the first Treatment Cycle
Change from Baseline to Day 43 in Myasthenia Gravis-Composite (MG-C) score within first 6 week treatment cycle
Change from Baseline to Day 43 in Quantitative Myasthenia Gravis (QMG) score within first 6-week treatment cycle
Change from Baseline to Day 43 in Myasthenia Gravis (MG) Symptoms Patient Reported Outcome (PRO) 'Muscle Weakness Fatigability' score within first 6-week treatment cycle
Change from Baseline to Day 43 in MG Symptoms PRO 'Physical Fatigue' score within first 6-week treatment cycle
Show 2 moreShow less
Percentage of participants with treatment-emergent adverse events (TEAEs)
Percentage of participants with TEAEs leading to withdrawal of investigational medicinal product (IMP)

Arms and interventions

RozanolixizumabExperimental

Participants will receive 6 dose per cycle of subcutaneous infusion of rozanolixizumab

Drugs: Rozanolixizumab

Sites

12 sites in 1 country